Abiraterone acetate plus prednisone (AAP) in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) and prior diethylstilbestrol (DES) therapy: Preliminary results
| Autor: | Francisco Gonzalez, Diogo Assed Bastos, Mariana Grings, Telma Murias Santos, Rosemarie Gidekel, Giovani Thomaz Pioner, Marcos Tobias Machado, Gustavo Werutsky, Renato Panhoca, Lizis Lopes |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
Cancer Research education.field_of_study medicine.medical_specialty Chemotherapy business.industry medicine.medical_treatment Population Diethylstilbestrol Abiraterone acetate medicine.disease Androgen deprivation therapy chemistry.chemical_compound Prostate cancer chemistry Prednisone Internal medicine medicine Hormone therapy education business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 36:235-235 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2018.36.6_suppl.235 |
| Popis: | 235 Background: AAP is approved for patients with chemotherapy-naïve mCRPC, but the population with previous use of DES was not studied before. DES is a commonly used hormone therapy for mCRPC in second and plus lines, especially in developing countries, due to lack of access to novel and efficacious therapies. The objective of this trial is to describe the efficacy and safety of AAP after DES treatment in patients who are chemotherapy-naïve, potentially affecting chemotherapy onset. This is the first and only prospective trial to show this data. Methods: This phase 2 multicenter, open-label single-arm study evaluated 46 patients receiving AA (1000 mg daily) + low-dose prednisone (P; 10 mg daily) and androgen deprivation therapy in patients with DES–refractory mCRPC enrolled from Oct 2014 to Oct 2015. The primary efficacy endpoint was time to prostate-specific antigen progression (PSAP) by Prostate Cancer Working Group (PCWG2) criteria. Secondary endpoints included PSA response (≥50% reduction), overall survival, and safety. Results: At baseline, median age was 69 years, median PSA was 40 ng/mL, there were no visceral metastases, 98% of patients had Eastern Cooperative Oncology Group Performance Status 0-1, and 44% had Gleason scores ≥7. Thirty two subjects (71.1%) had PSAP. PSA response was achieved by 47% of patients at week 12 and 56% at any time. Three patients remain on study drug and 4 are in follow-up. AA treatment continued until PSAP, clinical progression, consent withdrawal, or unacceptable toxicity. The median duration of study treatment was 8.6 months. The median time to PSAP was 7.4 months (95% CI = 5.6-9.4) and the median overall survival was 25.6 months (95% CI = 15.7-NE). Treatment-related adverse events included hypertension (19.6%), hyperglycemia (19.6%), fatigue (17.4%), and hypokalemia (4.5%); most grade 1-2. Conclusions: The present study confirmed that AAP provides PSA responses even in heavily treated patients, showing clinical benefit post-DES in chemotherapy-naive mCRPC patients. It also confirmed tolerability of AAP, with an easily manageable toxicity profile. Clinical trial information: NCT02217566. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|